The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Deletion of CDKN2A (p16) or amplification of CCND1 (cyclin D1) occurs commonly in head and neck squamous cell carcinoma (HNSCC) and induces sustained cyclin-dependent kinase (CDK) 4/6 activation. Here, we report the antiproliferative activity of LY2835219, a selective CDK4/6 inhibitor through inhibi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Ku, Bo Mi, Yi, Seong Yoon, Koh, Jiae, Bae, Yeon-Hee, Sun, Jong-Mu, Lee, Se-hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924753/
https://ncbi.nlm.nih.gov/pubmed/26909611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7543
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares